Whistleblower
Champions for the courageous
who report fraud.
Our nation’s whistleblower laws embody the wisdom that ordinary Americans are oftentimes best positioned to monitor and report on fraud.
Overview
Whistleblowers play an important role in reporting fraudulent activity and misconduct that harms the integrity of our markets. We represent individuals who want to provide inside information, as a whistleblower, to certain federal government agencies so that they might prosecute the possible fraud or misconduct. Providing such information may result in a monetary award for the whistleblower.
We work on claims involving:
- Securities & Investment Fraud
- Fraud in the Commodities & Futures Markets
- Money Laundering
- Health Care Fraud
- Government Contractor/Procurement Fraud
- Tax Fraud
Confidentiality
Reporting fraudulent activity can seem like a risky endeavor. We understand the stress and uncertainty that comes with deciding to report fraud. Be assured, when you entrust us with information about potentially fraudulent activity or misconduct, your confidentiality is of paramount concern throughout our initial consultation and throughout the reporting process. And we take appropriate measures to protect your confidentiality during any litigation concerning your whistleblower claims.
We represent clients on a contingency fee basis, and we do not charge a fee for an initial, no-obligation case evaluation that is fully confidential. We carefully evaluate each claim whistleblowers bring forward, heavily investing our time and resources to demonstrate our belief in a case’s value. We receive a fee only when we succeed on your behalf.
Fraud can be reported, and awards received, anonymously. While it is not necessary for a whistleblower to engage legal counsel at the time of reporting fraud, misconduct, or other violations, it is recommended. When reporting to the Securities and Exchange Commission, among other federal agencies, to apply for an award, legal counsel is required, if reporting is anonymous.
Qualifying for and receiving a reward under these laws requires a careful understanding of and adherence to each agency’s rules. Our experienced whistleblower attorneys stand ready to assist.
Current Cases
U.S.A. v. Janssen Biotech, Inc.
U.S.A. v. Janssen Biotech, Inc. (D. Mass.): Cohen Milstein represents the plaintiff-relator in a whistleblower/qui tam lawsuit against Janssen Biotech (a subsidiary of Johnson & Johnson), alleging that the manufacturer of the rheumatoid arthritis drugs Remicade and Simponi ARIA violated federal law by engaging in a scheme through which it provided physicians free practice management and infusion business consulting services over an extended period to induce the physicians to purchase Remicade and Simponi ARIA and administer these drugs to patients, including Medicare beneficiaries, via infusions performed in their offices.
U.S. ex rel. Pepe M.D. and Sherman, M.D. v. Fresenius Vascular Care, Inc., et al.
In 2022, the federal government and multiple state governments intervened in this qui tam action commenced by Cohen Milstein on behalf of the whistleblowers against Fresenius Vascular Care, Inc. and affiliated defendants, alleging that they violated the federal and state False Claims Acts by performing and billing Medicare and Medicaid for unnecessary surgical procedures that were not covered by these programs, that subjected patients to health risks, and that defrauded the government and taxpayers of many millions of dollars. The action seeks treble damages and civil penalties.
U.S.A. v. RegalCare False Claims Act Litigation
U.S.A. v. RegalCare False Claims Act Litigation (D. Mass.): Cohen Milstein represents the whistleblower in a FCA case against a skilled nursing management company, RegalCare, and its affiliated companies and executives, alleging that they systematically overbilled Medicare and Medicaid for years. Allegedly, during just three years, RegalCare received nearly $260 million in reimbursement for claims that were billed at the highest-level of therapy services. On February 18, 2025, the United States and the Commonwealth of Massachusetts intervened in the case with the filing of their own complaint.
Past Cases
USA, ex. rel., Lauren Kieff, et al. v. Wyeth
United States of America et al., ex rel. Lauren Kieff, v. Wyeth, No.1:03-CV-12366-DPW (D.Mass.): A qui tam action alleging that drug manufacturer Wyeth overcharged the state Medicaid programs by not providing them the statutorily required “best price” for a widely prescribed drug. This action resulted in a recovery of more than $780 million by the government.
USA, ex. rel. O’Connor v. National Spine and Pain Centers, LLC
United States of America ex rel. Michelle O’Connor v. National Spine and Pain Centers, LLC, et al. (E.D. Va.): Cohen Milstein represented the whistleblower, a physician assistant and former employee of PMA in this qui tam action. The whistleblower alleged that PMA, which operates several pain management practices in Virginia, doing business as National Spine & Pain Centers, overcharged Medicare, TRICARE, and the Federal Employees Health Benefits Program for medical services and ordered quantitative urine drug tests that were medically unnecessary, and which were billed to the federal health care programs. On April 19, 2019, the United States Government reached a settlement with PMA for approximately $3.3 million.
USA, State of Maryland ex rel. J. Doe v. Shore Health System, Inc.
United States of America and The State of Maryland ex rel. J. Doe v. Shore Health System, Inc. (D. Md.): Cohen Milstein represented the whistleblower who brought forward and filed a qui tam lawsuit, alleging that Shore Health System, a subsidiary of the University of Maryland Medical System that operates two hospitals and several non-hospital outpatient centers located on Maryland’s Eastern Shore, overcharged the Medicare and Maryland Medicaid programs between 2014 – 2018 for services provided to Medicare and dual eligible Medicare and Medicaid beneficiaries. On July 16, 2021, the Maryland U.S. Attorney’s Office and the State of Maryland reached a $9.5 million settlement.
News & INSIGHTS
Today’s news, tomorrow’s change.
Six Detroit Nursing Homes to Pay $4.5 Million to Settle Medicare/Medicaid Fraud Action
Cohen Milstein
U.S. CFTC: Division of Enforcement to Accept “Material” Self-Reporting Violations from CFTC Operating Divisions
Cohen Milstein
This Company Is Spending Millions to Profit Off Veterans’ Benefits. Why Won’t Lawmakers Stop It?
The War Horse